Feb 08, 2010
SuppreMol appoints Dr. Robert Phelps as Head of Business Development & Licensing

Sep 07, 2009
SuppreMol receives public research funding for its lead project SM101

Aug 31, 2009
Uwe Jacob resigned today from his position as Corporate Development Officer at SuppreMol.

January 11-15, 2010
PepTalk 2010, Pipeline 2: Protein Production; San Diego, California, USA

March, 8-10, 2010
BIO-Europe Spring 2010, Barcelona, Spain

April, 13-15, 2010
Biopharmaceutical Change Control, Post-Translational Modifications: Characterization, Manufacturing Support and Product Optimization, San Diego, California, USA

May 3-6, 2010
BIO International Convention 2010, Chicago, USA

Corporate Fact Sheet (en)
Corporate Fact Sheet (de)
Press Resources
Video on Suppremol

SuppreMol GmbH is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

At present, SuppreMol develops drug candidates for the treatment of autoimmune diseases such as Idiopathic Thrombocytopenic Purpura, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis and Psoriasis. Its lead product SM101 already is in clinical development.

The Company was founded in 2002 as a spin-off from the Max Planck Institute of Biochemistry and is located in Martinsried near Munich, Germany.